Breast cancer (BC) is the most common cancer and the prevalent type of malignancy among women. Multiple risk factors, including genetic changes, biological age, dense breast tissue, and obesity are associated with BC. The mitogen-activated protein kinases (MAPK) signaling pathway has a pivotal role in regulating biological functions such as cell proliferation, differentiation, apoptosis, and survival. It has become evident that the MAPK pathway is associated with tumorigenesis and may promote breast cancer development. The MAPK/RAS/RAF cascade is closely associated with breast cancer. RAS signaling can enhance BC cell growth and progression. B-Raf is an important kinase and a potent RAF isoform involved in breast tumor initiation and differentiation. Depending on the reasons for cancer, there are different strategies for treatment of women with BC. Till now, several FDA-approved treatments have been investigated that inhibit the MAPK pathway and reduce metastatic progression in breast cancer. The most common breast cancer drugs that regulate or inhibit the MAPK pathway may include Farnesyltransferase inhibitors (FTIs), Sorafenib, Vemurafenib, PLX8394, Dabrafenib, Ulixertinib, Simvastatin, Alisertib, and Teriflunomide. In this review, we will discuss the roles of the MAPK/RAS/RAF/MEK/ERK pathway in BC and summarize the FDA-approved prescription drugs that target the MAPK signaling pathway in women with BC.
The family of Tribbles proteins play many critical nonenzymatic roles and regulate a wide range of key signaling pathways. Tribbles homolog 2 (Trib2) is a pseudo serine/threonine kinase that functions as a scaffold or adaptor in various physiological and pathological processes. Trib2 can interact with E3 ubiquitin ligases and control protein stability of downstream effectors. This protein is induced by mitogens and enhances the propagation of several cancer cells, including myeloid leukemia, liver, lung, skin, bone, brain, and pancreatic. Thus, Trib2 can be a predictive and valuable biomarker for the diagnosis and treatment of cancer. Recent studies have illustrated that Trib2 plays a major role in cell fate determination of stem cells. Stem cells have the capacity to self-renew and differentiate into specific cell types. Stem cells are important sources for cell-based regenerative medicine and drug screening. Trib2 has been found to increase the self-renewal ability of embryonic stem cells, the reprogramming efficiency of somatic cells, and chondrogenesis. In this review, we will focus on the recent advances of Trib2 function in tumorigenesis and stem cell fate decisions.
Spinal Cord Injury (SCI), as a devastating and life-altering neurological disorder, is one of
the most serious health issues. Currently, the management of acute SCI includes pharmacotherapy and
surgical decompression. Both the approaches have been observed to have adverse physiological effects
on SCI patients. Therefore, novel therapeutic targets for the management of SCI are urgently required
for developing cell-based therapies. Multipotent stem cells, as a novel strategy for the treatment of
tissue injury, may provide an effective therapeutic option against many neurological disorders. Mesenchymal
stem cells (MSCs) or multipotent stromal cells can typically self-renew and generate various
cell types. These cells are often isolated from bone marrow (BM-MSCs), adipose tissues (AD-MSCs),
umbilical cord blood (UCB-MSCs), and placenta (PMSCs). MSCs have remarkable potential for the
development of regenerative therapies in animal models and humans with SCI. Herein, we summarize
the therapeutic potential of human MSCs in the treatment of SCI.
Spinal cord injury (SCI) as a serious public health issue and neurological insult is one of the
most severe cause of long-term disability. To date, a variety of techniques have been widely developed
to treat central nervous system injury. Currently, clinical treatments are limited to surgical decompression
and pharmacotherapy. Because of their negative effects and inefficiency, novel therapeutic approaches
are required in the management of SCI. Improvement and innovation of stem cell-based
therapies have a huge potential for biological and future clinical applications. Human pluripotent stem
cells (hPSCs) including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are
defined by their abilities to divide asymmetrically, self-renew and ultimately differentiate into various
cell lineages. There are considerable research efforts to use various types of stem cells, such as ESCs,
neural stem cells (NSCs), and mesenchymal stem cells (MSCs) in the treatment of patients with SCI.
Moreover, the use of patient-specific iPSCs holds great potential as an unlimited cell source for generating
in vivo models of SCI. In this review, we focused on the potential of hPSCs in treating SCI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.